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The objective of this study is to develop chitosaneanionic polymers based extended-
release tablets and test the feasibility of using this system for the sustained release of
highly water-soluble drugs with high drug loading. Here, the combination of sodium val-
proate (VPS) and valproic acid (VPA) were chosen as the model drugs. Anionic polymers
studied include xanthan gum (XG), carrageenan (CG), sodium carboxymethyl cellulose
(CMC-Na) and sodium alginate (SA). The tablets were prepared by wet granulation method.
In vitro drug release was carried out under simulated gastrointestinal condition. Drug
release mechanism was studied. Compared with single polymers, chitosaneanionic poly-
mers based system caused a further slowdown of drug release rate. Among them, CS
exanthan gum matrix system exhibited the best extended-release behavior and could
extend drug release for up to 24 h. Differential scanning calorimetry (DSC) and Fourier
transform infrared spectroscopy (FTIR) studies demonstrated that polyelectrolyte com-
plexes (PECs) were formed on the tablet surface, which played an important role on
retarding erosion and swelling of the matrix in the later stage. In conclusion, this study
demonstrated that it is possible to develop highly water-soluble drugs loaded extended-
release tablets using chitosaneanionic polymers based system.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction
Hydrophilic gel-formingmatrix tablets are widely used as oral
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concentration, viscosity and chemical structure of the poly-
mers, it is of greatly importance to select appropriate hydro-
philic polymers for the design of extended-release tablets.
Chitosan, a cationic biopolymer, derived from chitin by
partial deacetylation, is well known for its good biocompati-
bility, biodegradability, low toxicity and relatively low pro-
duction cost from abundant natural sources [2,3], and it has
been wildly applied as a polymeric drug carrier in the field of
pharmaceutics. However, although chitosan is a very prom-
ising biopolymer as a release-controlling agent in drug de-
livery, it has limited capacity for controlling drug releasewhen
used alone due to its easy disintegration characteristics at
neutral pH [4,5]. Thus, combination of CS with anionic poly-
mers as the carrier of oral controlled-release preparations has
been suggested, with increased controlled-release capability
and reduced pH dependence [6e8]. In most cases, extended-
release effect of the combination system was achieved by
forming the polyelectrolyte complexes (PECs) between CS and
anionic polymers in solution first and then the PECs was
further used for tablet preparation. Since PECs preparation
was an energy-consuming and lengthy process with compli-
cated operations [9], the superiority of simple preparation
process of this type of hydrophilic matrix tablets was greatly
discounted.
In order to avoid this drawback, some new strategies have
been taken. It was reported that when CSesodium alginate
(SA) physical mixture was used as the matrix to prepare tab-
lets, in situ PECs could be formed on the surface of the tablets
in the simulated gastrointestinal fluid due to selfeassembly or
spontaneous association [10]. However, drug release from this
CSeSA based system presented obvious drug solubility
dependence and it is not suitable to control the release of
highly water-soluble drugs [11]. Thus, it was absolutely
essential to search for alternative drug delivery system with
better extended-release ability for highly water-soluble drugs.
We assume that by changing the type of anionic polymers
used in combination with chitosan, it is possible to change the
strength and permeability of the PECs formed on the tablet
surface, therefore making the release of highly water-soluble
drugs under control as well. This hypothesis was tested in this
study.
Valproic acid (VPA) and sodium valproate (VPS) are
generally regarded as the first-line antiepileptic drugs [12].
Sodium valproate (VPS) is the sodium salt of 2-propyl pen-
tanoic acid with a high solubility (1000 mg/ml) in neutral pH.
They are usually used in combination [13]. Despite their ef-
ficacy for controlling epilepsy, they both suffer from relative
short half-life [14]. Thus, an extended-release preparation of
the combination has attracted considerable attention in
order to minimize plasma peak-related adverse effects and
reduce the inconvenience caused by frequent dosing of
conventional products. In addition, to meet the clinical needs
for once-daily administration, they were usually formulated
into extended-release dosage forms with high loading
(500 mg/tablet).
Therefore, in this study, by using VPA and VPS combina-
tion as the model highly soluble drugs, the feasibility of using
CS and other anionic polymers based system for controlling
the release of highly water-soluble drugs with high drugloading was tested, and influence of the type of anionic
polymers, CS: anionic polymer ratio, molecular weight of CS,
on the drug release behavior was screened, and drug release
mechanism from CS and anionic polymers based tablets were
further explored.2. Materials and methods
2.1. Materials
Chitosan (50 kDa, 100 kDa and 400 kDa) were all purchased
from Weifang Kehai Chitin Company, Ltd. (Weifang, Shan-
dong, China) with degrees of deacetylation of 86.5%, VPA and
VPS were purchased from Yan Cheng Lang De chemicals
Company, Ltd. SodiumAlginate (SA, LF 200M, G/M¼ 40:60) and
carrageenan (CG, GP 209NF) were gifts from FMC Biopolymer
Company, Ltd (Drammen, Norway). Sodium carboxymethyl
cellulose (CMC-Na) was from Anhui Shanhe Pharmaceutical
Excipients Co., Ltd (Anhui, China). Xanthan gum was from
Zibo Zhongxuan Biological Products Co., Ltd. (Shandong,
China). Magnesium stearate was from Tianjin Bo di Chemical
Company, Ltd. (Tianjin, China). Colloidal Silicon Dioxide was
purchased fromHubei ZhanWang Pharmaceuticals Company,
Ltd. (Hubei, China). All other chemicals were of analytical
grade.
2.2. Preparation of compound VPA and VPS extended-
release matrix tablets
The matrix tablets containing drug (500 mg calculated by VPS
and the mole ratio of VPS to VPA was 2/1), CSeanionic poly-
mers (200 mg), colloidal silicon dioxide (80 mg as adsorbent
and 11 mg as antisticking agent), magnesium stearate (11 mg)
as lubricants were prepared using conventional wet granula-
tion method. All the components used were passed through
80-mesh sieve andmixed for at least 15min, then 70% ethanol
was used as wetting agent to prepare the damp mass, the
granules were prepared by passing through 16mesh sieve and
dried at 55 C. The dried granules were mixed with lubricants
and compressed using single punch tableting machine (ZDY-
8, Shanghai far-east-pharmach company, Ltd., Shanghai,
China) with a caplet punch. Hardness of all the tablet formu-
lations was adjusted to 120e140 N (Shanghai Huanghai In-
struments Company, Ltd., Shanghai, China; hardness tester;
n ¼ 6). The weight of each tablet was controlled within
780 ± 0.5% mg.
2.3. In vitro drug release study
Drug release from the tablets was tested using a dissolution
apparatus (ZRD6-B, Shanghai Huanghai Instruments Com-
pany, Ltd, Shanghai, China), ChP Apparatus II (paddlemethod)
operating at 50 r/min and 37 ± 0.5 C. Unless specially indi-
cated, the tablets were immersed in dissolution vessels (n ¼ 6)
with simulated gastrointestinal conditions (500 ml of pH 1.2
HCl solutions for the first hour, 900 ml of pH 6.8 phosphate
buffer for additional 23 h) as dissolution medium. Aliquots of
10ml were withdrawn at different time intervals (0.5, 1, 2, 3, 4,
6, 8, 10, 12, 15, and 24 h) for analysis and were replenished
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drug released at different time intervalswas determined using
high-performance liquid chromatography (HPLC)method [15].
The differences in release profiles of the designed formu-
lations were compared using similarity factor (f2). The simi-
larity factor was calculated using the Eq. (1) [16].
f2 ¼ 50$log
nh
1þ

1
.
n
Xn
t¼1ðRt  TtÞ
2
i0:5
 100
o
(1)
where n is the number of time points, Rt is the dissolution
value of the reference at time t, and Tt is the dissolution value
of the test at time t. The release profiles were significantly
different if f2 < 50.2.4. Differential scanning calorimetry (DSC)
Thermal analysis was performed using a Mettler Toledo
model 30TC 15 equipment (Mettler, Zurich, Switzerland). The
samples (2e4 mg) were scanned in sealed aluminum pans
under nitrogen atmosphere. The sampleswere cooled to room
temperature and then reheated from 25 to 320 C at a constant
rate of 10 C/min.2.5. Fourier transforms infrared (FTIR) spectroscopy
The infrared absorption spectra of the samples were analyzed
using an FTIR spectrophotometer (IFS-55, Bruker Co., Ltd.,
Switzerland, Faellanden). The tablets were prepared by com-
pressing the samples with potassium bromide. The peak vari-
ation of adsorption between 400 and 4000 cm1 was detected.Fig. 1 e Influence of different anionic polymers on the
release of compound VPAeVPS from matrix tablets when
used alone.2.6. Erosion and swelling behavior of the combined
matrix
The erosion and swelling behaviors of the developed matrix
system were evaluated simultaneously by measuring the
amount of water uptake and weight loss in a dissolution
tester. Briefly, the weighed tablets were placed in the disso-
lution vessels and were taken out of the vessels at pre-
determined time intervals and weighed after removing the
excess liquid. Swollen tablets were dried at 50 C for 2 days
and then the weight of dried tablets was determined. The
erosion and swelling ratioswere calculated according to Eq. (2)
and Eq. (3), the remaining ratio was calculated according to Eq
(4) [17,18].
ERð%Þ ¼ ðW0 Wr WdÞ=W0  100 (2)
SRð%Þ ¼ ðWt WrÞ=Wr  100 (3)
RMð%Þ ¼ 100 ER (4)
Where ER is erosion ratio, SR is swelling ratio, RM is remaining
ratio,W0 is the initial weight of the dry tablet,Wd is the weight
of drug released at time t, Wr is the weight of remaining dry
tablet after swelling at time t, Wt is the weight of the swollen
matrix tablet at time t. The erosion and swelling studies were
carried out in triplicate for all the samples tested.3. Results and discussion
3.1. Evaluation of CSeanionic polymers as extended-
release system
The anionic polymers were indispensable components in this
matrix system and the choice of anionic polymers type was of
special importance in developing the controlled-release sys-
tem. In this study, three other kinds of anionic polymers
including xanthan gum (XG), carrageenan (CG), and sodium
carboxymethyl cellulose (CMC-Na) were chosen to combine
with CS (400 kDa) to explore their extended-release capability
for VPAeVPS, and compared with that of CSesodium alginate
(SA) based system.
First of all, by keeping the total amount of polymer in each
formulation 200 mg, influence of single anionic polymers on
drug release was investigated. As shown in Fig. 1, these poly-
mers presented diverse release behavior when used alone.
Among them, SA and CMC-Na could only control drug release
for 8e10 h due to their swelling and erosion characteristics
[19]. When CG or XG was used as the matrix, controlled drug
release up to 14 h can be achieved. However, none of these
anionic polymers has the capacity to extend drug release up to
24 h when used alone. This phenomenon can be explained by
the fact that drug release from conventional hydrophilic ma-
trix is mainly controlled by drug solubility, swelling and
erosion properties of the polymer [20]. For single anionic
polymer based matrix tablets, due to the poor gel-forming
ability and large extent of polymer erosion, together with the
high drug solubility (1000 mg/ml) at neutral pH, a large amount
of drug was released in a short period of time.
Thus, in order to further prolong drug release to 24 h,
combination of these anionic polymers with CS was subse-
quently investigated. Fig. 2 shows the drug release profiles
from the combined matrix systems at CS and anionic poly-
mers ratio 1:1. Compared with the results in Fig. 1, when CS
and these anionic polymers were used in combination, the
drug release behaviors were improved to different degrees
and the extended-release characteristics became more
Fig. 2 e Drug release profiles of compound VPAeVPS
extended-release tablets combining different anionic
polymers and CS as matrixes.
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release of highly water-soluble drugs from CSeSA systemwas
the fastest, with 93.8% of the drug released within 6 h. For the
CSeCMC-Na and CSeCG based systems, although the drug
release was slower than that of single polymer based systems,
most of the drugs were released in 12 h. In contrast, 24 h
sustained drug release was obtained by using CSeXG-based
matrix system. The mechanism for this extended-release
behavior was further explored in the followed studies.
3.2. Effect of CS and XG ratio on drug release
The ratio between CS and anionic polymers might greatly in-
fluence the hydration property and drug diffusion coefficient in
the extended-release system. Since drug release from CSeXG-
based tablets exhibited the best extended-release behavior,
therefore the CSeXG systemwas selected for this investigation.
Bykeeping the total amount ofCS (400kDa) andXGbeing 200mg
in each formulation, effect of CS/XG ratio at 3/1, 1/1, 1/3, on drug
release was evaluated and the results are shown in Fig. 3.Fig. 3 e Influence of chitosan and xanthan gum ratio on
compound VPAeVPS release from the matrix tablets.No significant difference in release was found when
changing the ratio of CS toXG from3/1 to 1/1 (f2¼ 92). Although
a slight fluctuation in drug release occurred when CS to XG
ratiowas 1/3, the similarly factorswere still larger than 50 (f2 (3/
1e1/3) ¼ 71, f2 (1/1e1/3) ¼ 67), indicating that the weak fluctuation
didnot lead to largedeviation fromthewhole trend.Thus, drug
release was less influenced by CS to XG ratio in the range
studied. CS: XG ratio 1:1 was selected for the followed studies.
3.3. Effect of CS molecular weight on drug release
The molecular weight (MW) of the polymer is directly related
to gel strength and is of great importance in drug release since
it is decisive for the passage of water through the gel layer
during swelling. In this study, keeping CSeXG ratio 1:1, effect
of chitosanmolecular weight on drug releasewas investigated
by using three kinds of CSwith low (50 kDa),medium (100 kDa)
and high (400 kDa) molecular weights. The release profiles are
presented in Fig. 4.
It was noted that no apparent difference in drug release
was found in the first 6 h and thereafter slightly decreased
release rate was observed with the increase of chitosan mo-
lecular weight. On the whole, the drug release profiles from
these three kinds of CS based systems was similar to each
other (f2 (CS LMWeMMW)¼ 67 > 50, f2 (CS LMWeHMW)¼ 69 > 50, f2 (CS
MMWeHMW) ¼ 74 > 50). It was reported that, for hydrophilic
matrices, gel strength determines the erosion capacity of the
polymer, while solubility of the drug incorporated into the
polymer matrix will govern the release mechanism [21]. Due
to the high solubility of VPS and its high loading, it might be
released from the tablets mainly by diffusion through the gel
layer [22]. This is in good agreement with the comparable drug
release profiles from different molecular weight chitosan
based systems.
3.4. Characterization of the CS/XG PECs
In our previous study, itwas found that the self-assembled PECs
film was formed on the tablet surface of CSeSA based system
during the dissolution process [10]. Therefore, based on theFig. 4 e Influence of chitosan molecular weight on drug
release from compound VPAeVPS extended-release
tablets.
Fig. 6 e FTIR spectra of (a) CS, (b) XG, (c) physical mixtures
of CS:XG 1:1, (d) the outer film of swollen tablets at 24 h
with CS: XG 1:1.
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sume that in situ PECs can be formed on the tablet surface of
CSeXG-based system. Indeed, insoluble white film (shell struc-
tures) was observed visually on the outer surface of the tablets
during thedissolution test, similarphenomenonwasreported in
CSeSA based system [11]. In order to identify the composition of
the film, FIIR and DSC were applied to characterize the physi-
cochemical properties of the films collected from tablet surface.
Fig. 5 shows DSC curves of CS, XG, physical mixtures of CS
and XG, and the outer layer of CSeXG-based matrix tablets
after 24 h of release test. An exothermic peak appeared at
approximately 310 C (Fig. 5a) corresponding to the degrada-
tion of CS [23]. Similarly, XG (Fig. 5b) presented the exothermic
peak of decomposition at 288 C [24]. As for the physical
mixture of CSeXG (Fig. 5c), due to the overlap of the
exothermic peaks of CS and XG, only a peak at 303 C was
found, indicating no obvious interaction between each other.
However, compared with the single polymers and physical
mixture, the outer layer of CSeXG-based matrix tablets
showed different properties (Fig. 5d). On one hand, although
the exothermic peak at 288 C was still visible, it was very
weak. On the other hand, a new broad peak ranging from 150
to 280 C appeared, which was significant distinguished with
the single exothermic peaks of CS and XG and similar to the
exothermic peak of PECs reported in the literature [11]. These
results implied the in situ PECs were formed on the surface of
the tablets during drug release process.
Moreover, FIIR was further used to demonstrate the for-
mation of PEC on the tablet surface. In the spectrum of CS
(Fig. 6a), the band situated at 1659 cm1 and 1605 cm1 were
assigned to the amine groups of the 2-aminoglucose unit and
the carbonyl group of the 2-acetaminoglucose unit, respec-
tively [25]. Meanwhile, the characteristic peak of XG at
1725 cm1 corresponding to C]O stretching vibration of car-
boxylic groups was presented in the spectrum of XG (Fig. 6b)
[26,27]. In comparison with IR spectra of the single polymers,
no new characteristic peak was found in the physical mix-
tures (Fig. 6c). However, in the spectrum of the outer shell of
the CSeXG-based tablets, the characteristic peaks of XG wereFig. 5 e DSC curves of (a) CS, (b) XG, (c) the physical mixtures o
with CS: XG 1:1.not apparent or even disappeared. Meanwhile, a new weak
peak at 1542 cm1 was observed, which might be attributed to
the ionic interaction between the ionized carboxylic groups
and the protonated amino groups (eNH3
þ) of CS [8,28]. These
results were in accordance with previous observations from
the PECs formed between poly(acrylic acid) or carrageenan
with CS [29,30].
Therefore, both visual observation and DSC, FTIR studies
suggested that PEC was formed in situ on the CSeXG based
matrix tablets.
3.5. Drug release mechanism
For traditional hydrophilic matrices, the erosion and swelling
of the polymeric carrier play an important role in controlling
drug release [4,31]. This study demonstrated that PECs can be
formed on the surface of CSeXG-basedmatrix tablets. It is notf CS:XG 1:1, (d) the outer layer film of CSeXG-based tablets
Fig. 7 e Erosion and swelling behavior of CSeXG (1:1) based
matrix tablets in SGF followed by SIF, a: Remaining ratio; b:
Swelling ratio.
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Therefore, the erosion and swelling properties of the selected
CSeXG-based system were further evaluated by weighing
method during the release process.
As shown in Fig. 7a, the remaining ratio was quite high in
the initial stage, 82.66% in 0e1 h, and then slowed down
gradually with erosion rate 2.38%/h in 1e6 h. The remaining
ratio was 68.07% at 6 h and no significant decrease was
observed in the followed time period. This is in great agree-
ment with our previous study indicating that the formation of
PEC on the tablet surface may prevent erosion in the later
stage [10,11], leading to further prolonged drug release.
Similarly, threeestage swelling processes were observed in
Fig. 7b. Initially, the tablets exhibited fast swelling behavior
and the swelling ratio increased almost linearly at a rate of
57.96%/h, and swelling ratio reached 474% at 6 h. Thereafter,
the swelling rate slowed down gradually with the average rate
being approximately 16.76%/h during 6e24 h. After 12 h, the
swelling ratio was almost leveled off and it was 775.4% at 24 h.
Taken together, it was found that swelling ratio increased
slightly with limited change in remaining ratio of the tablet
after 6 h. This can probably be explained by the preventing
function of the PEC formed on the surface of CSeXG based
tablets during drug release process. Meanwhile, this result
implied that complete PEC was formed in 6 h. Similarly, it has
been demonstrated that polyion complex formation in chito-
san and xanthan gum gel layer prevented over-swelling,
strengthened the wet matrices and sustained the drug
release [32]. Since the formation of the PECs was a progressive
and gradual process, significantly decreased erosion and
swellingwas only observed after its complete formation at 6 h.
Basedon theaboveanalysis, it canbeconcludedthat laterstage
drug release from CSeXG matrix based tablets were greatly
dependent on the properties of PECs on the tablet surface.4. Conclusions
In this study the feasibility of using CSeanionic polymers
based matrix system for sustained release of highly water-soluble drugs, the combination of sodium valproate and val-
proic acid were demonstrated. Among them, drug release
from CSeXG-based matrix system exhibited the best
extended-release behavior and was less influenced by the
change of CS: XG ratio and CS molecular weights. Differential
scanning calorimetry and Fourier transform infrared spec-
troscopy studies demonstrated that polyelectrolyte com-
plexes (PECs) were formed on the tablet surface. The PECs
played an important role on retarding erosion and swelling of
the matrix, and therefore drug release in the later stage. In
conclusion, CSeanionic polymer system was suitable for
developing extended-release preparations of highly water-
soluble drugs with high drug loading and this broadened
current views on hydrophilic polymers based matrix tablets.r e f e r e n c e s
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